A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

Summary

Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened clinical and pathological awareness. This study aims to summarize the clinical characteristics of LCNEC and analyze various prognostic factors to enhance understanding and vigilance toward this disease. Combined with precise pathological diagnosis, improving diagnostic accuracy is crucial for formulating treatment strategies and assessing patient prognosis.

Conditions

• Uterine Cervical Neoplasms

Interventions

OTHER

Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.

Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Cancer Research Institute of Zhongshan City

  collaborator OTHER_GOV

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Fujian Province Tumor Hospital

  collaborator OTHER

• Fujian Maternity and Child Health Hospital

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• The Third Affiliated Hospital of Kunming Medical College.

  collaborator OTHER

• Obstetrics & Gynecology Hospital of Fudan University

  collaborator OTHER

• Women's Hospital School Of Medicine Zhejiang University

  collaborator OTHER

• National Cancer Center/National Cancer Clinical Medical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

  collaborator UNKNOWN

• Peking Union Medical College Hospital

  collaborator OTHER

• The Affiliated Tumor Hospital of Xinjiang Medical University

  collaborator UNKNOWN

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Tianjin Medical University Cancer Institute and Hospital

  collaborator OTHER

• Renmin Hospital of Wuhan University

  collaborator OTHER

• Lili

  lead OTHER

Eligibility

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-01

Primary Completion

2028-11-01

Completion

2028-11-01